Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2611 to 2625 of 9102 results

  1. Secukinumab for treating moderate to severe hidradenitis suppurativa in people 12 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Mirikizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Bee venom immunotherapy for generalised or systemic IgE-mediated allergic reactions to bee venom

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Wasp venom immunotherapy for treating wasp venom allergy

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Venglustat for treating Fabry disease

    Awaiting development Reference number: GID-TA12452 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Orforglipron for managing overweight and obesity in people 12 to 17 years

    Awaiting development Reference number: GID-TA12451 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12450 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Cagrilintide–semaglutide for managing overweight and obesity

    Awaiting development Reference number: GID-TA12443 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression

    Awaiting development Reference number: GID-TA12444 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-HTG10902 Expected publication date: TBC

    HealthTech guidance
    In development

  11. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTG10886 Expected publication date:  04 February 2027

    HealthTech guidance
    In development

  12. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-HTG10898 Expected publication date: TBC

    HealthTech guidance
    In development

  13. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  23 February 2027

    NICE guideline
    In development

  14. Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments

    Awaiting development Reference number: GID-TA12461 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716

    In development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    In development